Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

CompletedOBSERVATIONAL
Enrollment

682

Participants

Timeline

Start Date

October 5, 2019

Primary Completion Date

February 7, 2022

Study Completion Date

February 7, 2022

Conditions
Influenza
Interventions
BIOLOGICAL

VaxigripTetra®

Suspension for injection Injection intramuscular

Trial Locations (12)

Unknown

Site 003, Gangwon-do

Site 002, Gwangju

Site 004, Gyeonggi-do

Site 005, Gyeonggi-do

Site 008, Gyeonggi-do

Site 011, Gyeonggi-do

Site 015, Gyeonggi-do

Site 006, Gyeongsangnam-do

Site 010, Gyeongsangnam-do

Site 009, Seoul

Site 012, Seoul

Site 014, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY